has been a hot topic of discussion by both ti1e Canadian Paediatric Society's Immunization and Infectious Disease Committee. and the National Advisory Committee on Immunization for a number of years. This prom ise of a new improved vaccine with less side effects being just around the come r· has been circu lating for over five years. When can we realistically expect a replacement for the whole-cell pertussis vaccine?
The whole -cell pertussis vaccin e has been used in Canada for over 50 years and is res ponsible for the reduction of pertussis cases by over 90% (1). Because of a high rate of adverse reactions associated witil the vaccine. considerable research h as taken place to develop a less reactogenic and equally effective vaccine. Much of the impetus for this research has been the concern that pertussis vaccine co uld ca use s ignificant and permanent neurological damage. Recent reviews of these data do not support such a n association (2) but the desire for an alternate vaccine continues because of the high rate of minor local and systemic adverse reactions following pertussis immunization (3) .
Many of the adverse reactions h ave been attributed to contaminating constituents and products of the causative bacterium BordeLella pertussis present in the whole-cell vaccine . New 'acellula r' vaccines are being fom1ulated which use purified a ntigens of the bacteria which have been shown to induce protective immunity in animals. These so-called protective antigens which are candidates for inclusion in new pertussis vaccines include pertussis toxin (in a toxoided form), filam entous hemagglutinin. fin1brtae and a 69 kDa membrane protein.
Acellular pertussis vaccines have been in \Vide -spread use in Japan for almost 10 years and have successfully controlled whooping cough in the immunized population. Two of these vaccines were tested in Sweden in a large efficacy study in the late 1980s. Although effective in protecting infants against
typical whooping cough. there was some concern that the vaccines were less effective than U1e whole -cell vaccine (which unfortunately was not included in tile study) (4) . Since that Lime , a number of new acellular vaccines have completed early clinical studies. The efficacy of several of these vaccines will be tested in large stuclies either underway or soon to begin in a number of countries. However. these studies will not be comp leted before the end of 1995 and licensure of ti1e vaccines (if they prove to be effective) cannot be expected until 1996.
On a related note. la rge local reactions are proving to be troublesome for recipients of booster doses of conventional diphtheria/pertussis/tetanus (OPT) vaccine . A recent study showed that 71% of children given a preschool (fifth) dose of OPT vaccine developed large injection site reactions. a nd soreness causing arm immobility occurred in 8% . Projected to the 400.000 ch ildren across Canada who receive this vaccine annually prior to school entry implies that over 30.000 have arms temporatily immobilized by pain. Fortunately, local symptoms resolve within a few days and are not usually accompanied by systemic adverse effects. The cause like ly rests with chan ges made to the vaccine when alum -containing products were introdu ced after 1980. High diphtheria toxoid content. has been identified as a contributor to vaccine reactions (5) but other constituents such as pertussis vaccine and a luminum phosphate may also be important.. Acellular pertussis DT vaccines might offer an early solution. Licensure is pending in U1e United States for such products to be used for booster doses only: even greater justification for this interim measure mig ht exist in Canada if new vaccines reduce local reactions.
Until acellular vaccines become available. all effo rts s h ould be made to ensure complete compliance with c urrent recommendation for the whole-cell pertussis vaccine which has been successful in limiting the morbidity and mortality of pertussis in Canada. Deferral of pertussis immunization should be limited to those infants who m eet valid contraindications for pertussis vaccine (6) .
